PharmiWeb.com - Global Pharma News & Resources

Medical comms - Press Releases

Date Title Company
01-May-2024 Significant POLB 001 Patent Granted in United States Poolbeg Pharma plc
30-Apr-2024 Beckman Coulter Life Sciences and Watchmaker Genomics Announce Partnership Beckman Coulter Life Sciences
30-Apr-2024 Transformative partnership between the Medicines Patent Pool and ViiV Healthcare enables 24 million people in low- and middle-income countries to access innovative HIV treatment ViiV Healthcare
30-Apr-2024 Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision ImmunomicsTM antigen discovery technologies to target five more cancers Infinitopes Precision Immunomics
30-Apr-2024 Locate Bio Raises £9.2 Million to Progress LDGraft Clinical Study for Anterior Lumbar Interbody Fusion Locate Bio
26-Apr-2024 Stockholm, Sweden – April 26 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid treatment for oral pain, today announces the appointment of Anna Asplind as Phase 3 Program Manager. OncoZenge
26-Apr-2024 HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda HUTCHMED
26-Apr-2024 Liebherr presents its innovative cooling solutions at Clinical Pharmacy Congress 2024 Liebherr
26-Apr-2024 eyeDNA Therapeutics to Present 2-year Follow-up Phase I/II Data on its Investigational Gene Therapy HORA-PDE6b for Retinitis Pigmentosa at the ARVO 2024 Annual Meeting eyeDNA Therapeutics
25-Apr-2024 Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024 Heidelberg Pharma
25-Apr-2024 BIAL appoints Pierluigi Antonelli as Non-Executive Board Member BIAL
25-Apr-2024 V-Bio Ventures leads €20 million Series A financing of Precision oncology company Flindr Therapeutics to advance first-in-class small molecule inhibitors V-Bio Ventures
25-Apr-2024 Cambridge Cognition spin-out Monument Therapeutics accesses £1.5m for schizophrenia clinical development Cambridge Cognition
25-Apr-2024 New £40M research centres will unlock new tests, treatments and cures for people living with rare diseases LifeArc
25-Apr-2024 LifeArc launches £40M research centres that will unlock new tests, treatments and cures for people living with rare diseases LifeArc
23-Apr-2024 AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at the ASGCT 2024 annual meeting AAVantgarde Bio
23-Apr-2024 CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy Janssen-Cilag International NV,
23-Apr-2024 BenevolentAI provides an update on its business priorities BenevolentAI
23-Apr-2024 Cambridge Cognition spin-out Monument Therapeutics accesses £1.5m for schizophrenia clinical development Cambridge Cognition Holdings plc
23-Apr-2024 MPE launches the Myeloma and AL Amyloidosis European Clinical Trial Navigator Myeloma Patients Europe (MPE)